mProX™ Human PDCD1LG2 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

PDCD1LG2, also known as PDL2, is an immunological checkpoint molecule that plays a role in regulating immune responses. Several studies have investigated the applications of PDCD1LG2 in different types of cancer. In hepatocellular carcinoma (HCC), PDCD1LG2 expression was found to be positively correlated with the expression of other immunological checkpoints and was associated with better sensitivity to immunotherapy agents. In ovarian cancer, a pyroptosis-related signature that included PDCD1LG2 was identified as a prognostic marker and was associated with immune responses. In colorectal cancer, PDCD1LG2 expression was found to be positively correlated with immune checkpoint molecules and was associated with immune activity in the tumor microenvironment. In gliomas, FCGR2B expression was positively correlated with PDCD1LG2 expression and other immune checkpoint molecules, and high expression of FCGR2B was associated with immunosuppression in the tumor microenvironment. In bladder cancer, ADRM1 expression was elevated in tumor tissues compared to adjacent tissues and was associated with worse overall survival. ADRM1 expression was also positively correlated with immune checkpoint molecules, immune infiltration, and tumor mutation burden, suggesting its potential as a biomarker and therapeutic target. Overall, these studies highlight the diverse applications of PDCD1LG2 in cancer research, including its role in predicting prognosis, evaluating the tumor immune microenvironment, and guiding treatment decisions.